Our response to COVID-19 | GSK https://www.gsk.

com/en-gb/media/our-response-to-covid-19/

GSK logo linking to the homepage

Home Media Our response to COVID-19

Our response to COVID-19

Since the pandemic began, we have sought ways to harness our scientific
expertise and technology to make a difference. Together with our partners we
are developing COVID-19 therapeutics and vaccines, and now have assets at
various stages of development, including three approved for use (in some
markets).

COVID

COVID-19 treatments
Through our collaboration with US immunology company Vir biotechnology,
we delivered a monoclonal antibody treatment for the early treatment of
COVID-19. Candidate selection to first emergency approval took less than 1.5
years.

Monoclonal antibodies are created in a lab and work in a similar way to the

1 of 7 4/13/23, 21:04
Our response to COVID-19 | GSK https://www.gsk.com/en-gb/media/our-response-to-covid-19/

human immune system to target a specific virus. They have played an

GSK logo linking to the homepage
important role in our pandemic response, offering a treatment option to
vulnerable patients who do not have a strong natural immune response to the
virus.

Adjuvanted COVID-19 vaccines

We partnered with several companies working on vaccines by providing them
with access to our adjuvant technology.

Adding an adjuvant to a vaccine can improve the immune system’s response

to the vaccine and may allow for more doses to be produced because a
smaller amount of vaccine is needed to generate immunity.

Together with Sanofi, our adjuvanted vaccine provides broad neutralising

antibody responses against currently known and tested variants of the virus.
This vaccine is indicated as a booster in the European Union and Great
Britain.

Our collaboration with SK bioscience has led to the development of an

adjuvanted vaccine that is approved in South Korea. SK bioscience has
submitted regulatory applications and intends to make the vaccine available
through the COVAX Facility, if the necessary approvals are granted.

mRNA COVID-19 vaccines

In addition to these adjuvanted vaccines, our work to develop new mRNA
vaccines includes a COVID-19 R&D programme with CureVac, which began
clinical trials in 2022. If successful, these mRNA vaccines would protect
against multiple COVID-19 variants. This agreement builds on a previously
established collaboration between GSK and CureVac to develop up to five
mRNA-based vaccines and monoclonal antibodies.

2 of 7 4/13/23, 21:04
Our response to COVID-19 | GSK https://www.gsk.com/en-gb/media/our-response-to-covid-19/

GSK logo linking to the homepage

You might also like

3 of 7 4/13/23, 21:04
Our response to COVID-19 | GSK https://www.gsk.com/en-gb/media/our-response-to-covid-19/

GSK logo linking to the homepage

RE SE ARCH AND DE VELOPMENT APPROACH

We focus our R&D on science of the immune system, human genetics

and advanced technologies to develop innovative vaccines and
medicines

4 of 7 4/13/23, 21:04
Our response to COVID-19 | GSK https://www.gsk.com/en-gb/media/our-response-to-covid-19/

GSK logo linking to the homepage

GLOBAL HE ALTH AND HE ALTH SECURIT Y

We have a unique and important role to play in helping to improve

global health and health security

5 of 7 4/13/23, 21:04
Our response to COVID-19 | GSK https://www.gsk.com/en-gb/media/our-response-to-covid-19/

GSK logo linking to the homepage

PARTNERING WITH GSK

We partner with scientific institutions, national health systems,

academia and industry to develop vaccines and medicines

6 of 7 4/13/23, 21:04
Our response to COVID-19 | GSK https://www.gsk.com/en-gb/media/our-response-to-covid-19/

GSK logo linking to the homepage

This is our global website, intended for visitors seeking information on GSK's worldwide business.  Our market sites can be
reached by visiting our location selector.  

© 2001-2023 GSK plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies.

GSK plc. Registered in England and Wales No. 3888792.

Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.

Modern Slavery Act statement 2022 (PDF - 189.7KB)

7 of 7 4/13/23, 21:04